Evidence map›Paper›PMID 35214650›Full record

ArticleVaccines2022

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study.

Farah M Shurrab, Duaa W Al-Sadeq, Haissam Abou-Saleh, Nader Al-Dewik, Amira E Elsharafi, Fatima M Hamaydeh, Bushra Y Abo Halawa, Tala M Jamaleddin, Huda M Abdul Hameed, Parveen B Nizamuddin and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. A novel and safe SmartCapFrontiers in immunology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Farah M ShurrabBiomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar.
Duaa W Al-SadeqBiomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-0487-3365
Haissam Abou-SalehBiomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0003-3460-1413
Nader Al-DewikWomen's Wellness and Research Center (WWRC), Clinical and Metabolic Genetics Section, Pediatrics Department, Hamad General Hospital (HGH), Interim Translational Research Institute (iTRI), Hamad Medical Corporation (HMC), College of Health and Life Science (CHLS), Hamad Bin Khalifa University (HBKU), Doha P.O. Box 3050, Qatar.ORCID 0000-0001-5739-1135
Amira E ElsharafiDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0003-4523-2748
Fatima M HamaydehDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
Bushra Y Abo HalawaBiological Science Program, Department of Biological and Environmental Sciences, College of Arts and Science, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-8758-3303
Tala M JamaleddinDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-9272-1168
Huda M Abdul HameedDepartment of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
Parveen B NizamuddinBiomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar.
Fathima Humaira AmanullahBiomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar.
Hanin I DaasCollege of Dental Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0001-9074-2726
Laith J Abu-RaddadInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha P.O. Box 24144, Qatar.ORCID 0000-0003-0790-0506
Gheyath K NasrallahBiomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0001-9252-1038
Qatar University · QACornell University · USHamad General Hospital · QA

Funding

Qatar National Research Fund UREP28-173-3-07
6 · The paper itself

Abstract

The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (

Indexed as

Moderna-mRNA-1273neutralizing antibodiesPfizer-BNT162b2SARS-CoV-2vaccine

Identifiers

PMID35214650
PMCPMC8877530
OpenAlexW4210803241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.